These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 16892890)

  • 1. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
    Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K
    Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic growth factors for chemotherapy-induced neutropenia.
    Yalçin S
    Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
    Liang DC
    Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia.
    Stull DM; Bilmes R; Kim H; Fichtl R
    Am J Health Syst Pharm; 2005 Jan; 62(1):83-7. PubMed ID: 15658078
    [No Abstract]   [Full Text] [Related]  

  • 5. Myeloid growth factors.
    Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
    J Natl Compr Canc Netw; 2009 Jan; 7(1):64-83. PubMed ID: 19176207
    [No Abstract]   [Full Text] [Related]  

  • 6. Interactive discussion on chemotherapy-related adverse events.
    Adams VR; Lyman GH
    Pharmacotherapy; 2000 Jul; 20(7 Pt 2):121S-125S. PubMed ID: 10905688
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colony-stimulating factors stimulate some treatments, continue to evolve.
    Volkers N
    J Natl Cancer Inst; 1999 Feb; 91(3):210-2. PubMed ID: 10037097
    [No Abstract]   [Full Text] [Related]  

  • 9. [Place of CSF in pediatric oncology].
    Hartmann O; Valteau-Couanet D
    Pathol Biol (Paris); 1993 Jan; 41(1):52. PubMed ID: 7686289
    [No Abstract]   [Full Text] [Related]  

  • 10. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors.
    Ozer H
    Curr Opin Hematol; 1996 Jan; 3(1):3-10. PubMed ID: 9372045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic use of hematopoietic growth factors.
    Costa JJ
    J Allergy Clin Immunol; 1998 Jan; 101(1 Pt 1):1-6. PubMed ID: 9449493
    [No Abstract]   [Full Text] [Related]  

  • 12. [G-CSF in oncology].
    Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
    Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte colony-stimulating factors.
    Med Lett Drugs Ther; 1991 Jun; 33(847):61-3. PubMed ID: 1710761
    [No Abstract]   [Full Text] [Related]  

  • 14. [Preventing and treating hematologic complications of anticancer chemotherapy: update on hematopoietic growth factors].
    Spaëth D; Geoffrois L; Conroy T
    Bull Cancer; 2000 Jan; 87(1):93-6. PubMed ID: 10673637
    [No Abstract]   [Full Text] [Related]  

  • 15. Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.
    Freyer G; Ligneau B; Trillet-Lenoir V
    Int J Antimicrob Agents; 1998 Apr; 10(1):3-9. PubMed ID: 9624538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?
    Croockewit AJ; Koopmans PP; de Pauw BE
    Clin Pharmacol Ther; 1996 Jan; 59(1):1-6. PubMed ID: 8549028
    [No Abstract]   [Full Text] [Related]  

  • 17. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth factor frenzy.
    Quesenberry PJ
    Exp Hematol; 1993 Jul; 21(7):835-6. PubMed ID: 7686499
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy-induced neutropenia: new approaches to an old problem.
    Ozer H
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):1-2. PubMed ID: 14508713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.